From November 13 to 15, 2019, the three-day first annual meeting of the 12th Yiyang Nursing Professional Committee and Nursing Innovation Management Seminar was successfully held at Huatian Hotel under the careful organization and arrangement of the Yiyang Nursing Association and the Municipal Nursing Quality Control Center.
* U.S. stocks fell across the board, with the Dow falling more than 400 points;
* The sell-off in U.S. Treasuries continues, with the 10-year U.S. Treasury yield approaching 4.40%;
*The S&P 500 energy sector index closed higher for the 13th consecutive week, the longest streak in history.
U.S. stocks fell across the board on Friday, with heavyweights such as Nvidia and Microsoft dragging down the market. As the U.S.-Israeli war against Iran enters its fourth week, market concerns about the risks of rising inflation and interest rate hikes have further intensified. The Nasdaq and the Dow both fell into correction territory during the session, and their declines narrowed before the close.
As of the close, the Dow Jones Industrial Average fell 443.96 points, or 0.96%, to 45577.47 points, the Nasdaq fell 2.01% to 21647.61 points, and the S&P 500 Index fell 1.51% to 6506.48 points. The S&P 500 has fallen for four consecutive weeks, its longest weekly losing streak since March 2025. The Dow Jones Industrial Average has fallen for four consecutive weeks, setting a record for its longest weekly losing streak since February 2023.
Friday coincides with the quarterly "Triple Witching Day", when stocks, stock index options and futures derivatives contracts expire simultaneously, amplifying trading volume and exacerbating market volatility. All three major U.S. stock indexes fell below their 200-day moving averages, highlighting the continued deterioration of market sentiment on Wall Street. The Russell 2000 index of small-cap stocks fell 1.6%, retracing more than 10% from its all-time closing high set on January 22.
[Performance of popular stocks]
Star technology stocks performed poorly, with Apple falling 0.39%, Microsoft falling 1.84%, and Meta, Google, Nvidia and Tesla falling more than 2%.
Amazon fell 1.62%. According to reports, the technology giant launched its first smartphone, aiming to compete with Apple and Samsung.
Energy stocks performed strongly, with the S&P 500 energy sector index closing up for the 13th consecutive week, setting a record for the longest time in history. This was mainly affected by geopolitical events in Venezuela and the Middle East that dominated the market in the first quarter.
The Nasdaq China Golden Dragon Index fell 2.92%, Baidu fell 3.99%, and Alibaba, NetEase, and JD.com fell more than 2%.
【Market Overview】
The conflict in the Middle East shows no signs of easing. According to CCTV News, U.S. Department of Defense officials have formulated detailed preparation plans for the deployment of U.S. ground troops to Iran. However, the situation changed after the market closed. According to Xinhua News Agency, U.S. President Trump posted on social media on the 20th that "we are very close to achieving our goal" and that the United States is considering gradually downgrading military operations against Iran.
Jack Dolarhyde, chief executive of Longbow Asset Management, said: "The market finally recognized that this conflict may last much longer than originally expected, which is why the stock market sold off. The war may not only last a few weeks, but even last for months."
Fed officials also acknowledged that the conflict complicates policymaking. Federal Reserve Governor Christopher Waller said he was originally prepared to vote for an interest rate cut at the Fed meeting due to an unexpected decline in employment data, but the escalating oil shock pushed up the risk of inflation, causing him to change his stance. Although U.S. policymakers still expect to cut interest rates by at least 25 basis points this year, the market is less confident about this.
U.S. bond yields rose further. The 2-year U.S. bond, which is closely related to interest rate expectations, rose 9.7 basis points to 3.893%, and the benchmark 10-year U.S. bond rose 13.5 basis points to 4.390%. The conflict in the Middle East has supported high oil prices and further intensified the market's concerns about inflation. The Chicago Mercantile Exchange's Fed Watch tool shows that U.S. interest rate futures pricing shows that by the end of 2026, the probability of the Fed raising interest rates is higher than the probability of cutting interest rates.
Patrick Garvey, head of global interest rate and debt strategy at ING, said: "The current environment is a typical upward interest rate environment, and the core driving force is oil prices pushing up inflation expectations. And the war has entered its fourth week, which means that this kind of market pressure is difficult to dissipate in the short term."
Robert Pavlik, senior portfolio manager at Dakota Wealth Management, said: "Many people believe that rising inflationary pressure will force the Federal Reserve to raise interest rates, but I think this is unlikely because this round of inflation is not a demand-side problem. It is a supply problem... Only by reopening the Strait of Hormuz and restoring the flow of crude oil can the upward pressure on oil prices be alleviated."
As the first quarter draws to a close, investors are assessing the impact of higher oil prices on corporate earnings. "The longer this continues, the more companies will begin to disclose cost pressures in their financial reports, and this pressure may be transmitted to the entire industry chain," said Joe Saluzzi, co-head of equity trading at Themes Trading Company.
In terms of other stocks, FedEx, which is regarded as an economic barometer, issued an optimistic performance outlook, saying that despite geopolitical tensions, global demand remained solid, pushing its stock price up 0.77%.
【Bulk Performance】
Crude oil continued its gains. The price of light crude oil futures for April delivery on the New York Mercantile Exchange rose by US$2.18 to close at US$98.32 per barrel, an increase of 2.27%; the price of London Brent crude oil futures for May delivery rose by US$3.54 to close at US$112.19 per barrel, an increase of 3.26%.
Expectations of interest rate hikes continue to weigh on the precious metals market. COMEX gold futures for May delivery on the New York Mercantile Exchange fell below $4,500 in late trading, down 2.5%. They fell nearly 11% this week and entered a technical bear market. COMEX silver futures fell 4.7% and were trading around $67.80.
In today's digital financial era, many people are accustomed to conducting financial transactions through WeChat or Alipay. However, if you don’t have a WeChat account or an Alipay account, but still want to get funds through the borrowing app, there is still a way. The key is that you need to have a bank card. Because the loan services provided by most borrowing apps are to transfer money directly to the borrower's bank account, rather than transferring money through WeChat or Alipay. Therefore, as long as you have a bank account, whether you use WeChat or Alipay, you can try to apply for a loan on these borrowing platforms.
It is worth noting that although not having a WeChat or Alipay account may impose certain restrictions on your loan application, many borrowing platforms will accept real-name authentication and mobile phone numbers as part of identity verification. This usually means that you only need to complete the corresponding registration process and verify your identity with your mobile phone number to start applying for a loan. In addition, some platforms may also require you to upload a photo of your ID card or provide other identity proof materials to complete real-name authentication.
Nevertheless, in order to ensure that you successfully pass the review and obtain a loan, it is recommended that you carefully read the relevant terms and conditions of the loan platform before applying to understand the loan interest rate, repayment method and any additional fees that may exist. At the same time, plan the use of your funds reasonably to avoid falling into financial difficulties due to excessive borrowing.
In addition, it is also very important to choose a borrowing platform with good reputation and reasonable interest rate. You can help you make a more informed choice by checking the platform’s user reviews, loan interest rates, repayment terms and other information. In some cases, you can also borrow through a platform recommended by friends or family, which often increases your chances of success.
In short, as long as you have a bank account and can complete identity verification through real-name authentication and mobile phone number, even if you do not have a WeChat or Alipay account, you still have the opportunity to obtain the funds you need through the loan APP. However, before applying, be sure to carefully consider your repayment capabilities and borrowing risks to ensure that you can properly manage your personal finances while obtaining a loan.
From November 13 to 15, 2019, the three-day first annual meeting of the 12th Yiyang Nursing Professional Committee and Nursing Innovation Management Seminar was successfully held at Huatian Hotel under the careful organization and arrangement of the Yiyang Nursing Association and the Municipal Nursing Quality Control Center. More than 380 representatives from nursing deans, directors of nursing departments, head nurses and nursing backbones from various medical institutions at all levels in the city attended the meeting.
The conference received strong support from the Yiyang Municipal Health Commission, Yiyang Medical Association and the affiliated unit Yiyang Central Hospital. Tang Donghua, deputy director of the Municipal Health Commission, Zeng Yuehong, president of the Municipal Medical Association, Tian Haiqing, president of the Central Hospital, and Yang Lianqiu, deputy president, attended the opening ceremony and delivered important speeches. The opening ceremony was hosted by Li Yangping, secretary-general of the Medical Association. The results of the 12th general election of the Yiyang Nursing Professional Committee were read out at the meeting. Liu Manshi, director of the Nursing Department, was elected as the chairman of the new Nursing Professional Committee.
The clinical nursing practice case competition is a highlight of this conference. On the evening of the 13th, in the conference room on the first floor of the Internal Medicine Building of Yiyang Central Hospital, the city’s nursing elites gathered together in a warm atmosphere. 13 case presenters from 12 units across the city participated in the competition. This is the first clinical nursing practice case competition organized by our city. It is to showcase the latest clinical nursing practice results, promote and apply them throughout the city, and greatly improve the city's nursing technology level. After fierce competition, the three cases from our institute won the special prize, second prize and third prize respectively. The special prize case "Extracorporeal Manipulation Combined with Intracavitary Electrocardiographic Positioning Technology to Reset the Ectopic PICC Catheter in Newborns" and the first prize case "We Have a Tip for Standardized Insulin Injection" were shared at the Nursing Innovation Management Conference.
Nursing management innovation and academic lectures will bring this conference to a climax. The content covers nursing quality and safety, leadership change, nursing technology operation, deep vein thrombosis prevention and treatment, palliative care, narrative care, catheter fixation, critical patient transport care, etc. Li Lezhi, deputy dean of the School of Nursing of Central South University, was specially invited to teach "Common Issues in Hospital Review". The course content is novel in design, close to the actual clinical and management needs, and brings the latest concepts to everyone, leading everyone to change and improve.
This meeting also arranged a sharing session on nursing experience in hospitals at all levels. Yiyang Central Hospital, Taojiang County People's Hospital, and Medical College Affiliated Hospital respectively introduced their successful experiences in nursing management. Director Chen Guochun of Kangya Hospital shared his experience in nursing learning in Taiwan. During the meeting, Director Liu Manshi and Director Liu Xihe also organized a new working meeting of the Nursing Society and Quality Control Center members to deploy and arrange future work. The members communicated with each other, offered ideas and suggestions, and put forward constructive opinions and suggestions to jointly create a nursing blueprint for the development of the city's nursing industry.
This conference, whether it was special lectures, experience sharing, learning discussions, or case competitions, fully demonstrated the latest achievements in the field of nursing in our city, and had a strong inspiration and promotion effect on the nursing management work of hospitals at all levels. The Nursing Society and the Quality Control Center will continue to play a leading role and lead the city's nursing workers to "remain true to their original aspirations, keep their mission in mind, and forge ahead."
On March 19 (Thursday) local time, the leaders of the 27 EU countries held a summit in Brussels. The initial core issue of the summit was to resolve Hungary's opposition to Ukraine's huge loan. However, the conflict between Iran and Lebanon continued to ferment, and the global oil and gas prices caused by the superimposed war soared, making Middle East-related issues quickly occupy the core of the summit.
Belgian Prime Minister Balte de Wever expressed his views on the energy crisis on the eve of the summit. He said: "Energy prices were already at high levels before the war broke out, and this conflict has ushered in a new round of skyrocketing prices. If this kind of increase becomes the norm, we will be in trouble."
1. The 27 EU countries refuse to be involved in military operations in the Middle East
As a key waterway for global energy transportation, the Strait of Hormuz carries about 20% of the world's oil and liquefied natural gas trade and is also an important channel for European energy imports.
In response to U.S. President Trump's request for the EU to send military forces to help ensure security in the Strait of Hormuz, the leaders of the 27 EU countries are generally critical of Iran, but they are not willing to immediately provide military support to the United States.
European Commission Vice President and EU High Representative for Foreign Affairs and Security Policy Kaya Callas pointed out that leaders of various countries have no intention to expand Europe's naval power in the Red Sea. Whether it is to help ensure the security of the Strait of Hormuz or to be involved in war in other ways, it will be difficult to gain consensus within the EU.
2. Statements from all parties
According to confirmation by the Associated Press and Agence France-Presse, the United Kingdom clearly refused to be dragged into this dispute, while France stated that it would consider it after the war subsided.
Austrian Chancellor Christian Stockel took a tough stance, saying at the meeting: "Europe, including Austria, will never be coerced into joining the military operations of the United States and Israel in the Middle East. Military intervention in the Strait of Hormuz is not within the scope of Austria's considerations."
German Chancellor Friedrich Mertz made it clear that Germany would only consider assisting in maintaining smooth waterways and other related matters after the war is over.
He said: "We will only commit to providing support when the guns have subsided and the weapons have been stockpiled. At that time, we can provide a lot of help, including opening and maintaining the safety of shipping lanes, but we will never take any action while the war continues."
He added that such assistance requires first obtaining international authorization and completing a series of complex processes.
Although Dutch Prime Minister Rob Yetten understood the original intention of the United States and Israel to launch military operations against Iran, he did not express support. Instead, he called on the European Union to increase sanctions on Iran and strengthen support for Iranian opposition groups.
Spanish Prime Minister Pedro Sánchez clearly opposed the war, saying it violated international law.
He said: "We oppose this war because it is illegal. The war not only brings serious disasters to civilians and triggers a flow of refugees, but its economic impact also sweeps the world, especially countries in the global South."
Latvian Prime Minister Evica Silinja revealed that Trump has mentioned that he hopes NATO will support the cleanup of the Strait of Hormuz, but has not yet made a formal request to the EU.
Silenya said if a formal request is received, it will be fully evaluated.
Guest author - Taoist priest
In "Four major precautions in the seventeen different states of the App!" | Collection Level Part 1" (click "Read the original text" at the end of the article to view), we have taken stock of all the states of the App and sorted out the operating procedures and precautions in some common states. Today we will add the remaining states. At the same time, Qimai Research Institute has sorted out the App state corresponding process, so developers can check the actual conditions of their own Apps accordingly.
Because after passing the review, it is divided into "automatic release" and "manual release", for the convenience of presentation, the status of "waiting for agreement", "waiting for Apple release" and other states are concentrated after "passing review" in the flow chart.
Common status operation procedures and precautions
Developer Removed From Sale
The "Removed by Developer" status text generally appears after the App enters the "Available for Sale" stage.
steps involved
1. Cancel the sale status in all regions in the "App Information" area, or click "Remove".
2. Operate the App alone to remove it from the shelves in one or several countries and regions.
Note 1
1. For apps that have been "removed from the shelves" by the developer, the developer can re-list the product at any time.
2. When the App status changes, you will receive the corresponding notification content in the email. The screenshot below is the screenshot content received after being "removed by the developer".
Removed From Sale
The difference between "removed from the shelves" here and "removed from the shelves by developers" is that products "removed from the shelves by developers" can be re-listed at any time during iTC operations, while "removed from the shelves" require re-submission of information for review or communication, and may no longer be allowed to be put on the shelves.
steps involved
1. After the removed product is removed from the shelves, the email address of the account holder to whom the App belongs and the account holder bound to receive App status notifications will receive a notification.
2. The status of the App will be changed to the text "Removed", and the explanation of the reason for being removed and the terms violated will also be pushed in the "iOS Version" - "Solution Center".
Note 2
1. Products that have been removed from the shelves cannot be directly put on the shelves and need to submit a new version for review, and the new version review will encounter a certain delay in review.
2. The account owned by the App after being removed from the shelves may be marked, and there is a certain probability that the account will be banned by Apple.
Rejected (New message from App Review)
The "Rejected" status generally appears after the App enters the "Under Review" status. After Apple's review, it is found that the product experience or functions in the App do not meet the specifications, or the App metadata does not meet the specifications. If the App is rejected through review, "Rejected by the App" is further divided into "Metadata Rejected" or "Binary Folder Rejected".
Note 3
1. The difference between "rejected" and "rejected by the developer" here is that "rejected" is rejected by Apple. If you want to re-enter the review, you must modify the areas where Apple raised questions and meet Apple standards. Only then can you pass the review.
2. "Rejected by the developer" generally means rejection after review or rejection after review. Rejection after review can be resubmitted immediately. Before the problem is pointed out by Apple, it can enter the review status normally and pass the review. If there are problems, it will enter the "rejected" status;
3. Rejection after passing review generally means that the developer is not satisfied with the currently reviewed version, or finds that there are problems with the version, so he can reject this version and resubmit it for review. When the resubmission enters "Waiting for Review" or "Under Review", the developer can also initiate the "Rejected by Developer" operation. If it is rejected by Apple after entering "Under Review", it will enter the "Rejected by Apple" state.
Metadata Rejected
The "Metadata Rejected" status generally appears after the App is submitted for review and enters "Under Review". If the metadata of the App reviewed by Apple does not meet the requirements, the App review will be rejected and the "Metadata Rejected" status will be returned.
Note 4
1. If metadata is rejected, you generally only need to modify the relevant content of the metadata. There is no need to resubmit for review. Just reply to Apple in "iOS Version" - "Solution Center".
2. Corresponding to "Metadata Rejected" is "Binary File Rejected". The latter is generally a significant bug in the App, or content or functions that do not meet the requirements. If the App content is modified and the build version is re-uploaded, you need to re-submit for review after selecting the latest build version. If the build version is not re-uploaded, you can reply to Apple in "iOS Version" - "Solution Center".
3. In recent years, when Apple rejects Apps, they no longer differentiate between "Metadata Rejected" and "Binary File Rejected", but have changed them to "Binary Folder Rejected". Therefore, when encountering the "Rejected" status, you should understand the reason for rejection clearly and correct it before resubmitting or replying to solve the problem.
Developer Rejected
The "Rejected by Developer" status generally appears when the App is submitted for review and enters "Waiting for Review" or "Under Review" before rejecting the currently submitted version for review, or after the App passes review and rejects the currently approved version.
For apps that some developers no longer want to operate, they can select the "Remove App" button at the bottom of the App's "App Information" page.
For "Removed" Apps, there will be a separate category to display the content of the "App". If the App's status is "Available for Sale" or "Removed by Apple" and no new version has been added, and when the App's status is "Removed", "App
The "Information" interface will display the locked status in the content section.
If the App has not been online and is currently in the "Removed" state, the "App Information" interface will not display a content box in the content section.
write at the end
In the App Store Connect backend, in order to allow developers to understand the status of their apps more clearly and intuitively, Apple uses indicators in three colors: red, yellow, and green.
When trading stocks, look at Jin Qilin’s analyst reports, which are authoritative, professional, timely and comprehensive, helping you tap into potential theme opportunities!
On September 28, 2020, Amic was listed on the GEM with a market value of 40.8 billion yuan. In the following nine months, the stock price soared 4 times. In March 2021, it became the third thousand-yuan stock after Moutai, with a peak market value exceeding 170 billion. This company, dubbed "Moutai for Medical Aesthetics", wrote a legend in the capital market during the golden age of medical aesthetics with its ultra-high gross profit margin of 94.85% and net profit margin of 60%.
The core secret of Amic's success lies in the moat built by the registration certificate of Class III medical devices. Its signature product "HiTi", as the first neck wrinkle repair injection in China, has monopolized the market for a long time since it was approved in 2016. Between 2017 and 2020, revenue from solution products soared from 34 million to 447 million, with an average annual compound growth rate of 129%. This "exclusive market + pricing power" model perfectly replicates Moutai's core logic. However, with the continuous emergence of similar competing products, Amic’s high-growth myth is gradually reaching its final chapter.
The myth of high growth is no longer the revenue and net profit growth rate dropped to single digits for the first time
The annual report disclosed on March 19 shows that Amic will achieve operating income of 3.026 billion yuan in 2024, with the year-on-year growth rate plummeting from 47.99% in 2023 to 5.45%; net profit attributable to the parent company is 1.958 billion yuan, with the growth rate slipping from 47.08% to 5.33%. This is the first time since 2016 that the company's annual revenue and net profit growth has dropped to single digits.
What is particularly noteworthy is that in the fourth quarter, the company's single-quarter revenue was 650 million yuan and net profit was 372 million yuan, a year-on-year decrease of 7% and 15.47% respectively, setting a quarterly double decline record for the first time since its listing. Judging from previous quarterly data, Amic’s growth stall has actually been evident for a long time. In the first quarter of 2024, the company's revenue growth rate was 28.24%, and the net profit growth rate was 27.38%; in the second quarter, the company's revenue growth rate was 2.35%, and the net profit growth rate was 8.03%; in the third quarter, the company's revenue growth rate was 1.10%, and the net profit growth rate was 2.13%. In 2024, the growth rate last year showed a trend of declining quarter by quarter.
Judging from the cash flow situation, the company's net cash flow from operating activities in 2024 will be 1.927 billion yuan, a year-on-year decrease of 1.38%, which is the first year-on-year decline in history. The reasons behind this include a significant increase in period expenses and an increase in inventory. In terms of period expenses, the company's sales expenses and R&D expenses in 2024 will be 277 million yuan and 304 million yuan respectively, both reaching record highs. However, from the perspective of results, the marginal effect of sales expenses driving revenue growth is weakening, and the growth rate of sales expenses in 2023 and 2024 is higher than the revenue growth rate.
Research and development expenses have maintained a year-on-year double-digit growth rate in the past three years, but new products have not yet formed large-scale revenue, and it may be difficult to bring substantial benefits in the short term. In terms of inventory, the company's inventory at the end of 2024 was 72.843 million yuan, accounting for an increase of 0.14% to 0.87% of total assets. Among them, the ending inventory of goods was 32.0488 million yuan, a year-on-year increase of about 45%. Display terminal sales have slowed down.
"High Body" cannot reverse its decline by exchanging price for volume. "Wet Day Angel" has weak growth
Judging from the products, as the first neck wrinkle repair product in China, Amic’s “HiTi” was once the company’s “cash cow”. After being launched in 2017, its sales soared from 119,700 units to 5.14 million units in 2023, accounting for more than 70% of revenue at one time. However, the 2024 annual report data disclosed that the annual sales volume of solution injection products with "Hi Body" as the core was 6.3463 million units, a year-on-year increase of 24.44%, but the revenue only increased by 4.4% to 1.744 billion yuan.
The converted average ex-factory price dropped to 275 yuan/piece from 325 yuan/piece in 2023, a decrease of 15.4%. During the same period, inventory increased significantly by 91.40%. It can be seen that since Huaxi Biotechnology’s neck wrinkle repair product “Runzhi·Gege” was approved in July 2024, the market competition landscape has been facing reshaping, and Amic’s price-for-volume strategy has had very limited results.
Judging from the revenue structure of Amic, in 2024, the company's solution injection products with "High Body" as the core and gel injection products with "Moisturizing Angel" as the core will achieve revenue of 1.743 billion yuan and 1.216 billion yuan respectively, accounting for 57.64% and 40.18% of total revenue respectively, which are the company's pillar businesses.
Among them, "Moistening Angel" (cross-linked sodium hyaluronate gel containing L-lactic acid-ethylene glycol copolymer microspheres) obtained the Class III medical device registration certificate in June 2021. In the following years, product revenue showed a rapid growth trend and is regarded as the company's second growth curve. However, "Soaking Angel" also experienced sluggish growth in 2024. The sales volume of gel injection products in 2024 was only 893,600 units, a year-on-year decrease of 11.24%, and the revenue growth rate also plummeted from 81.43% in 2023 to 5.01%.
From an industry perspective, the pressure on Amic's two core products is a concentrated reflection of the increasing market competition, slowing industry expansion, and tightening supervision. Hyaluronic acid was once the "golden track" of the medical aesthetics industry, but now it has fallen into serious involution. As of 2024, more than 50 hyaluronic acid Class III medical device certificates have been approved domestically, and there are more than 400 circulating brands. This has also led to an increase in the choice of medical aesthetics institutions, and the bargaining power of upstream manufacturers has continued to weaken.
From the perspective of industry growth, a review of the medical aesthetics industry in 2024 shows that affected by the macro environment, the overall growth rate of the industry has slowed down significantly. According to estimates by Allergan and Deloitte, the overall growth rate of the medical aesthetics market in 2024 is about 10%. Although it still maintains double-digit growth, it has dropped significantly compared with the 20% growth rate in 2023. At the regulatory level, in 2024, the State Food and Drug Administration will strengthen the approval of the "Three Device Certificates" to crack down on illegal medical beauty institutions, and the pressure on upstream manufacturers to rectify channels will increase significantly.
The plight of Aimeike is essentially the epitome of the medical beauty industry entering its mature stage from the outbreak period. As the medical beauty industry enters the second half of its journey, the era of "making money while lying down" will be gone forever. At present, about 98% of Amic's revenue still relies on hyaluronic acid products. Among the 10 products under development mentioned in the annual report, only Bonida 2.0 for chin filling will be approved at the end of 2024. However, this product is essentially an expansion of the indications of existing products and is not a revolutionary innovation.
Among the company's reserve products, botulinum toxin, collagen and other products are facing fierce competition, making it difficult to cultivate popular varieties similar to "High Body". It is still doubtful whether the acquisition of 85% equity of South Korea's REGEN company at a high premium of 1.386 billion can open a new growth curve. Under the new market competition landscape, Amic still faces many challenges if it wants to maintain its leading position in the industry.
Most U.S. Stocks Closed Lower On February 19, Crude Oil Rose, Trump May Use Force Against Iran2026-02-27Comments(0)
Quantitative Giant Lingjun Investment Is Once Again Caught In A Storm Of Public Opinion, Responding To Rumors Of Rumors And Trading Restrictions2026-03-07Comments(0)
Zheng Yongshi Almost Became The Fifth Concubine Of The Gambling King. What Is Her Current Situation After Leaving?2026-02-17Comments(0)